HPLC-ELSD法测定夜关门中D-松醇的含量

目的:建立高效液相色谱-蒸发光散射检测器(HPLC-ELSD)测定夜关门中D-松醇含量的方法。方法:样品用乙醇-水(70∶30)提取1.0 h后过滤,滤渣再用63%的乙醇-水提取1 h过滤,合并2次滤液并浓缩,定容;采用Cosmosil Sugar-D柱进行分离,乙腈-水(70∶30)为流动相,流速为1 mL·min-1,ELSD漂移管温度55℃,载气为氮气。结果:D-松醇在0.377～1.844μg呈现良好的线性关系(r=0.999 5),精密度为0.22%,加标回收率为96.78%。结论:该方法操作简单、准确度和灵敏度高、适合于D-松醇的检测和含量测定。     

湖北海棠提取物HPLC指纹图谱研究

目的建立湖北海棠提取物指纹图谱。方法采用高效液相色谱法,建立湖北海棠提取物指纹图谱,并进行相似度分析。结果确定了湖北海棠提取物10批样品指纹图谱共有模式,且相似度均在0．9以上。结论所建立的指纹图谱为制定湖北海棠提取物的质量标准提供依据。     

大分割放疗联合EP方案化疗治疗局限期小细胞肺癌的临床疗效及安全性

Objective To investigate the efficacy and safety of hypofractionated thoracic radiotherapy combined with EP chemotherapy in the treatment of limited-stage small-cell lung cancer (LS-SCLC). Methods A total of 117 patients with LS-SCLC were enrolled and randomly divided into test group (n=59) and control group (n=58). Patients in the experiment group were given hypofractionated thoracic radiotherapy combined with EP chemotherapy, while patients in the control group were given hyperfractionation radiotherapy combined with EP chemotherapy. Objective response rate (ORR), 2-year overall survival (OS), 2-year progression free survival (PFS), and immune cell level were used to evaluate clinical efficacy. We compared the incidence of side effects between the two groups. Results After the treatment, the ORR of patients in the test group was higher than that in the control group (P>0.05). The mean OS and PFS of patients in the test group were significantly longer than those in the control group (P<0.05). The levels of CD3+, CD4+, CD4+/CD8+, and NK cells in the test group were significantly higher, whereas the levels of CD8+ were significantly lower than those in the control group (P<0.05). The incidence of radiation pneumonitis, radiation esophagitis, and severe dermatitis in the test group was significantly lower than that in the control group (P<0.05). Conclusion Hypofractionated radiotherapy combined with EP chemotherapy for treatment of LS-SCLC can effectively improve the anticancer efficacy and patient survival, reduce the damage to the body’s immune function, and alleviate adverse reaction of radiotherapy. © 2023, CHINA RESEARCH ON PREVENTION AND TREATMENT. All rights reserved.     

雌激素受体突变型乳腺癌的耐药机制及其治疗策略

乳腺癌作为一种女性发病率最高的恶性肿瘤，严重威胁全球女性的健康。雌激素受体(Estrogen receptor, ER)阳性乳腺癌是其中占比最高的一种亚型，其发展受ER信号通路调控，临床治疗上除手术切除外还可辅以药物治疗。降低雌激素水平或拮抗ER功能的内分泌疗法是针对ER+乳腺癌的经典药物疗法，临床应用广泛且效果明确，但是在治疗中产生的耐药性在晚期或转移性乳腺癌中不可避免，其中一个关键耐药机制为ESR1(编码ERα的基因)基因突变，促使受体形成配体非依赖性激活构象并招募共激活分子，促进下游乳腺癌细胞生长、增殖和转移相关基因转录表达，导致抗雌激素治疗敏感性和有效性降低，目前抵抗突变耐药性乳腺癌的相关药物处于开发中。本综述重点探讨ERα激活性突变产生的耐药机制，总结了目前针对突变型ER+乳腺癌的有效治疗策略，为突变耐药性乳腺癌的治疗提供一定的思路。